Skip to main content

Table 3 Comparative analysis between patients’ groups with and without studied cytogenetic abnormalities regarding different parameters

From: Clinical impact of early minimal residual disease detection at day 15 in precursor B-childhood acute lymphoblastic leukemia: an Egyptian experience

ParametersCytogenetic abnormalitiesFisher exact test
Patients without the studied cytogenetic abnormalities (56)Patients with the studied cytogenetic abnormalities (16)P valueSig.
N%N%
Age (years)< 147.1%425.0%0.335NS
1–93867.9%850.0%
> 101425.0%425.0%
SexMale3053.6%1275.0%0.424NS
Female2646.4%425.0%
HepatomegalyAbsent3053.6%212.5%0.053NS
Present2646.4%1487.5%
SplenomegalyAbsent3257.1%425.0%0.228NS
Present2442.9%1275.0%
LymphadenopathyAbsent1221.4%425.0%1.000NS
Present4478.6%1275.0%
CNS infiltrationAbsent5292.9%1275.0%0.207NS
Present47.1%425.0%
Aberrant expression in (IPT)Negative4071.4%1275.0%1NS
Positive1628.5.%425.0%
Risk classificationStandard risk3257.2%00%0.009S
High risk2442.8%16100%
OutcomeGood4071.4%425.0%< 0.001S
Bad1628.5%1275.0%
Laboratory parameters
Parameters ttest
MeanSDMeanSDPvalueSig
Hb (gm/dL)7.631.917.901.810.722NS
TLC (× 109/L)36.1825.4887.5435.29< 0.001S
Platelets (× 109/L)78.7129.4650.3823.320.017S
PB blasts (%)34.6824.6223.3819.680.198NS
BM blasts (%)74.0017.8062.2519.510.116NS
BM blasts at day 15(%)2.964.0911.637.800.016S
  1. No./n number, NS non-significant, Sig significance. P ≥ 0.05 = NS; P < 0.05 = S; P ˂ 0.01 = HS; SD standard deviation, TLC total leukocytic count, Hb hemoglobin, IPT immunophenotyping, PB peripheral blood, BM bone marrow